Literature DB >> 26134747

Multiple sclerosis and Parkinson's disease: the two faces of neurodegeneration. Report of the first Greek case and review of the literature.

Anastasia Bougea1, Elisabeth Kapaki2, George P Paraskevas2, Kostas Kilidireas2, Elisabeth Andreadou2.   

Abstract

There is still an open debate whether multiple sclerosis (MS) lesions can cause parkinsonian symptoms, or the coexistence of both diseases in the same patient is accidental. Moreover, α-synuclein (α Syn), the hallmark of Parkinson's disease (PD) seems also to play a crucial role in MS. So far, 42 cases of co-occurrence of parkinsonism and MS have been reported, but CSF α Syn measurement is lacking. To our knowledge, we report the first case with concomitant MS and PD diagnosis based on both clinico-radiological and CSF α Syn findings and review of literature.

Entities:  

Keywords:  Cerebrovascular liquid (CSF); Multiple sclerosis (MS); Neurodegeneration; Parkinson’s disease (PD); a-Synuclein (α Syn)

Mesh:

Substances:

Year:  2015        PMID: 26134747     DOI: 10.1007/s10072-015-2308-9

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  10 in total

1.  Parkinsonism in multiple sclerosis.

Authors:  P Vieregge; W Klostermann; H Brückmann
Journal:  Mov Disord       Date:  1992-10       Impact factor: 10.338

2.  Multiple sclerosis and risk of Parkinson's disease: a Danish nationwide cohort study.

Authors:  N M Nielsen; B Pasternak; E Stenager; N Koch-Henriksen; M Frisch
Journal:  Eur J Neurol       Date:  2013-09-19       Impact factor: 6.089

Review 3.  Movement disorders in multiple sclerosis.

Authors:  C C Mao; S T Gancher; R M Herndon
Journal:  Mov Disord       Date:  1988       Impact factor: 10.338

4.  Upregulation of alpha-synuclein in neurons and glia in inflammatory demyelinating disease.

Authors:  Dimitrios Papadopoulos; Lisa Ewans; Danielle Pham-Dinh; Johanna Knott; Richard Reynolds
Journal:  Mol Cell Neurosci       Date:  2006-02-28       Impact factor: 4.314

5.  Decreased levels of alpha-synuclein in cerebrospinal fluid of patients with clinically isolated syndrome and multiple sclerosis.

Authors:  Roubina Ch Antonelou; Evangelia Emmanouilidou; Gerasimos Gasparinatos; Theodora Velona; Konstantinos I Voumvourakis; Leonidas Stefanis
Journal:  J Neurochem       Date:  2015-06-11       Impact factor: 5.372

6.  Role of α-synuclein in neurodegeneration: implications for the pathogenesis of Parkinson's disease.

Authors:  Shun Yu; Piu Chan
Journal:  Essays Biochem       Date:  2014       Impact factor: 8.000

7.  Cerebrospinal fluid α-synuclein levels are elevated in multiple sclerosis and neuromyelitis optica patients during replase.

Authors:  Honghao Wang; Kai Wang; Wen Xu; Conghui Wang; Wei Qiu; Xiaonan Zhong; Yongqiang Dai; Aimin Wu; Xueqiang Hu
Journal:  J Neurochem       Date:  2012-04-19       Impact factor: 5.372

8.  Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis.

Authors:  N Evangelou; D Konz; M M Esiri; S Smith; J Palace; P M Matthews
Journal:  Brain       Date:  2000-09       Impact factor: 13.501

9.  Chronic progressive multiple sclerosis - pathogenesis of neurodegeneration and therapeutic strategies.

Authors:  Dirk Fitzner; Mikael Simons
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

10.  The diagnostic value of CSF α-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease.

Authors:  Elisabeth Kapaki; George P Paraskevas; Evangelia Emmanouilidou; Kostas Vekrellis
Journal:  PLoS One       Date:  2013-11-25       Impact factor: 3.240

  10 in total
  2 in total

Review 1.  Movement Disorders in Multiple Sclerosis: An Update.

Authors:  Ritwik Ghosh; Dipayan Roy; Souvik Dubey; Shambaditya Das; Julián Benito-León
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2022-05-04

Review 2.  Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy1.

Authors:  Kurt A Jellinger
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.